COMPASS FINANCIAL MANAGEMENT LLC’s Dyne Therapeutics DYN Stock Holding History

COMPASS FINANCIAL MANAGEMENT LLC’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.5K	Buy	+724	New	+$13.5K	﹤0.01%	929

Other funds holding DYN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

COMPASS FINANCIAL MANAGEMENT LLC's DYN Position: Q2 2026 in Review

COMPASS FINANCIAL MANAGEMENT LLC opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 724 shares worth $17.5K. The stake represents ﹤0.01% of the portfolio and ranks #929 among its holdings.

137 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

COMPASS FINANCIAL MANAGEMENT LLC held 724 shares of Dyne Therapeutics worth $17.5K as of Q2 2026.
Dyne Therapeutics was a new COMPASS FINANCIAL MANAGEMENT LLC position in Q2 2026.
Dyne Therapeutics made up ﹤0.01% of COMPASS FINANCIAL MANAGEMENT LLC's portfolio in Q2 2026, its #929 holding.
137 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on COMPASS FINANCIAL MANAGEMENT LLC's 13F filing for Q2 2026, filed 12 Aug 2026.